Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344065 | 0.85 | MEN1 (0.45) | MEN1KMT2AGRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29937253 | 0.85 | MEN1 (0.45) | MEN1KMT2AGRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22029116 | 0.85 | KMT2A (0.45) | MEN1KMT2AGRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1922080 | 0.77 | SMN1; SMN2 (0.56) | MEN1KMT2AGRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL501694 | 0.76 | NPSR1 (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3641427 | 0.72 | MEN1 (0.45) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL29344067 | 0.72 | MEN1 (0.45) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL3635339 | 0.70 | GRIN2D (0.60) | SMN1; SMN2ALDH1A1NPC1MAPTHPGD | |
| SCHEMBL11584879 | 0.70 | NPC1 (0.68) | MEN1KMT2AGRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31118684 | 0.70 | MEN1 (0.43) | MEN1KMT2AALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2164840-A2 | MODULATORS OF CFTR | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166516-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | MEN1 4699/4885KMT2A 4596/4885GRM1 3942/4885 |
| US-20150031708-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | MEN1 4699/4885KMT2A 4596/4885GRM1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.